Understanding henipavirus surface proteins and their role in infections
Official title: Structure, function, and antigenicity of emerging henipavirus surface glycoproteins
Funded at Ohio State University · NIH-11313041 · Data updated 2026-11-12
This study is looking at specific proteins from henipaviruses, which can make both people and animals sick, to help create better vaccines and treatments to prevent future outbreaks.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | March 1, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $597,757 |
| NIH project number | 7U01AI173348-03 |
| Project ID | NIH-11313041 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at risk of exposure to henipaviruses, such as healthcare workers and those in close contact with infected animals.
✕Less likely to help
Patients who are not at risk of exposure to henipaviruses or those with existing immunity to these viruses may not receive direct benefits from this research.
What this research studies
This research investigates the structure and function of surface glycoproteins from henipaviruses, which are zoonotic viruses that can cause severe outbreaks in humans and animals. By analyzing these proteins, the research aims to develop effective vaccines and monoclonal antibodies to combat potential future pandemics. The study employs advanced techniques such as cryo-electron microscopy to visualize the proteins and understand how they interact with host cells. This knowledge is crucial for creating targeted treatments and preventive measures against henipavirus infections.
Why it matters
Potential benefit: If successful, this research could lead to the development of vaccines and treatments that significantly reduce the risk of henipavirus outbreaks and improve public health safety.
How similar studies have gone: Previous research on similar viral glycoproteins has shown promise in developing effective vaccines and treatments, indicating that this approach could be successful.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Xu, Kai — Ohio State University
- Study coordinator: Xu, Kai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.